“…Of the 73 patients who underwent definitive resection, 30 experienced a recurrence with site of first recurrence local only in 3%, locoregional in 22%, distant in 44%, and both locoregional and distant in 22%. 22 Additionally, Hill et al 34 recently published a large retrospective series of 155 patients who underwent SBRT to a median dose of 33 Gy for borderline-resectable and locally advanced pancreatic cancer followed by surgical resection. Although the authors found locoregional failures in 33% of patients, local only failures were uncommon (14%) as the first site of progression.…”